PAP 2023: Corey Ford Discusses Part D Requirements at Access PAP 2023

Engaging the full workforce—from HR to R&D—can elevate launch outcomes, build trust, and create long-term brand ambassadors.

Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

The US president says the levies on pharmaceutical imports are imminent, but won’t take effect for a year to a year and a half.

Vibhu Tewary offers insight on this market segment, including a behind-the-scenes of what goes into designing a report.

A qualitative study explores how MA plan leaders, kidney care managers, and dialysis providers perceive the benefits, risks, and marketing practices surrounding MA enrollment for patients with end-stage kidney disease.

As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.